NICE recommends spevigo for rare and severe psoriasis flares
Ella Day | June 20, 2025 | News story | Medical Communications, Research and Development | Dermatology, NHS, National Institute for Health and Care Excellence, generalised pustular psoriasis
The National Institute for Health and Care Excellence (NICE) has recommended Spevigo (spesolimab) for the treatment of generalised pustular psoriasis (GPP) flares in adults in England and Wales. This decision marks a significant milestone, providing patients with the first targeted therapy for this rare skin condition.
GPP is a severe form of psoriasis characterised by widespread, painful pustules on inflamed, reddened skin. Unlike plaque psoriasis, GPP flares can come on suddenly and may be accompanied by fever, fatigue and systemic inflammation, sometimes requiring emergency care.
Spesolimab is the first treatment to target the IL-36 pathway, offering rapid relief of GPP flare symptoms and achieving complete pustule clearance in a significant proportion of patients versus placebo in trials of the candidate.
Helen McAteer, chief executive of the Psoriasis Association, stated: “This rare and often unpredictable condition can have a devastating impact on quality of life. The approval marks a major step forward in addressing a significant unmet need and offers real hope to patients who have long awaited treatment options and the possibility of greater stability and peace of mind.”
The recommendation follows last week’s Spending Review announcement, which will increase NHS funding by 3% per year — allowing greater investment in NICE-approved innovative medicines that deliver improved outcomes for patients and value for the NHS.
Ella Day
20/6/25
This article featured in: July 2025 – The Pharmafile Brief
Related Content
A community-first future: which pathways will get us there?
In the final Gateway to Local Adoption article of 2025, Visions4Health caught up with Julian …
The Pharma Files: with Dr Ewen Cameron, Chief Executive of West Suffolk NHS Foundation Trust
Pharmafile chats with Dr Ewen Cameron, Chief Executive of West Suffolk NHS Foundation Trust, about …
Is this an Oppenheimer moment for the life sciences industry?
By Sabina Syed, Managing Director at Visions4Health In the history of science, few initiatives demonstrate …
